ClinicalTrials.gg
CompletedNCT04960280Updated Oct 20, 2026Results posted

A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease

An interventional study of ©VoqX stethoscope in Isolated Aortic Stenosis and Mitral Regurgitation, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 20, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.

Enrollment
14th of 81
400 · median 60
Started
2021
with 8 others
No phase
64 of 118
21 open now
Registered
89th of 118
by date
Lead sponsor
5 of 118
Mayo Clinic

Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 14th largest by enrollment of the 81 interventional ones that give a count, is one of 9 that started in 2021, is one of 64 with no phase, and was the 89th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Mitral Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether recording heart sounds with an acoustic stethoscope, combined with artificial intelligence (computer information), will show similar abnormalities to an echocardiogram or cardiac catheterization.

Read the detailed description

In the current study the plan is to recruit 600 patients who have been referred to the echocardiogram laboratory for routine clinically indicated echocardiography, or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures. Individuals with normal heart structure and sounds, isolated aortic stenosis (of varying severity), and isolated mitral regurgitation (of varying severity) will be included, while excluding individuals who have multiple valve involvements or combined valve pathologies. Each patient will have baseline testing using the ©CompuSteth device, which will be used to auscultate and record each patient's heart sounds at the bedside prior to the index echocardiogram or cardiac catheterization procedure. This process will take less than 10 minutes and is outlined below. Patients will then proceed with their clinically indicated echocardiograms or cardiac catheterization procedures.

Amongst the first 200 study participants, the results of the echocardiograms and invasive cardiac catheterization procedures will be used to train the ©VoqX device to identify normal heart and to screen and grade for various cardiac structural pathologies, aortic stenosis, and mitral regurgitation, diagnosed by gold-standard testing. Subsequently, after the ©VoqX device has been trained how to characterize and identify sounds that correspond to various structural cardiac pathologies, the next step is to prospectively 'test' how well the ©VoqX device is able to screen normal heart from cardiac pathologies, such as aortic stenosis, and mitral regurgitation, and identify the severity of the valve disorder in the subsequent 200 participants of the study. This will be done by comparing the results obtained from auscultation with the ©VoqX device against the results obtained from gold-standard testing with echocardiography or invasive cardiac catheterization.

03

Conditions studied

  • Isolated Aortic Stenosis
  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years of age or older.
  • Referred to the echocardiogram laboratory for routine clinically indicated echocardiography, or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures
  • Individuals with normal heart sounds, isolated aortic stenosis (any degree of severity), or isolated mitral regurgitation (any degree of severity)

Exclusion criteria

Exclusion Criteria

  • Patients with unstable cardiovascular or pulmonary disease
  • Patients with mixed valvular heart disease, corresponding to more than one type of valve pathology (i.e.: Aortic stenosis and Aortic Regurgitation), or more than 1 valve involved (i.e.: aortic stenosis and mitral regurgitation)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Computerized Auscultation

    Patients presenting to the echocardiogram laboratory for routine clinically indicated echocardiography or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures will undergo a computerized auscultation using the ©VoqX stethoscope and will have their heart sounds auscultated and recorded.

    Device: ©VoqX stethoscope

Interventions

  • Device©VoqX stethoscope

    Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.

06

What researchers measure

Primary outcomes

  1. The Number of Subjects Who Completed Baseline Testing With the ©VoqX Stethoscope

    The number of subjects who completed baseline diagnostic testing with the ©VoqX stethoscope.

    Time frame: Baseline

07

Results

Posted Oct 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneComputerized Auscultation
Started400
Completed400
Not completed0

Outcome measures

PrimaryThe Number of Subjects Who Completed Baseline Testing With the ©VoqX Stethoscope

The number of subjects who completed baseline diagnostic testing with the ©VoqX stethoscope.

Time frame:
Baseline
Reported as:
Count of participants · Participants
The Number of Subjects Who Completed Baseline Testing With the ©VoqX Stethoscope
ParticipantsComputerized Auscultation
The Number of Subjects Who Completed Baseline Testing With the ©VoqX Stethoscope400

Adverse events

Collected over Adverse events were collected from the time of informed consent through study completion, approximately 30 minutes.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Computerized Auscultation0/400 (0%)0/400 (0%)0/400 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Computerized Auscultation
<=18 years0
Between 18 and 65 years144
>=65 years256
Sex: Female, Male
Sex: Female, Male(Participants)Computerized Auscultation
Female155
Male245
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Computerized Auscultation
Hispanic or Latino4
Not Hispanic or Latino392
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Computerized Auscultation
American Indian or Alaska Native4
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American5
White384
More than one race0
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)Computerized Auscultation
United States400
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2024, 31 months.

Results were first posted in Oct 2026, 2 years 5 months after primary completion.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2021
First posted
Jul 13, 2021
StartActual
Sep 3, 2021
Primary completionActual
May 2, 2024
CompletionActual
Dec 17, 2025
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore collecting computerized auscultation data in a time-efficient manner at the bedside is feasibleNow The Number of Subjects Who Completed Baseline Testing With the ©VoqX StethoscopeTime frame: 2 years → Baseline
Oct 20, 2026
Documents
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore collecting computerized auscultation data in a time-efficient manner at the bedside is feasibleNow The Number of Subjects Who Completed Baseline Testing With the ©VoqX StethoscopeTime frame: 2 years → Baseline
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04960280
Lead sponsor
Mayo Clinic
Responsible party
Rajiv Gulati (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jul 13, 2021
Start date
Sep 3, 2021
Primary completion
May 2, 2024
Completion
Dec 17, 2025
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Rajiv Gulati, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion